Description of use

PD-L1 IHC is used as an aid in identifying non-small cell lung cancer patients for treatment options. The PD-L1 protein expression is determined by using a Tumor Proportion Score (TPS) which is the percentage of viable tumor cells with visible partial or complete membrane staining. Assessing this stain can be challenging due to the complex apperance, various PD-L1 antibodies, multiple scoring systems and treatment cutoff points. The PD-L1 APP automatically analyses the whole slide, by discriminating patient tissue from controls, identifying the viable tumor cells and calculating the TPS to reduce the subjectivity of visual evaluation, reducing intra-observer and inter-observer variability.